Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nong Yang

Showing results (61-70 of 208) with videos related to

Pageof 21
Sort By:
Clinical Therapeutics|October 27, 2010
The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover studyKun-Yan Li, Jian-Ping Liang, Bing-Qiang Hu, et al.
Natural Product Research|August 25, 2022
Flavonoids from the fruits of <i>Phyllanthus acidus</i> (L.) Skeels with anti-<i>α</i>-glucosidase activityJia Xu, Ying Xin, Hong-Tao Zhu, et al.
Tumori|January 29, 2021
Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspectiveYing-Hui Tong, Hai-Ying Ding, Wen-Xiu Xin, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 30, 2020
Pharmacokinetic and bioequivalence study of new S-1 capsule in Chinese cancer patientsYong Chen, Yun Jiang, Jingjing Qu, et al.
Oncotarget|February 1, 2018
The serum activity of thioredoxin reductases 1 (TrxR1) is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancerGong Chen, Qiong Chen, Fanxu Zeng, et al.
BMC Cancer|September 5, 2022
Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker studyYongchang Zhang, Lianxi Song, Liang Zeng, et al.
Translational Lung Cancer Research|March 18, 2024
Intracranial response pattern, tolerability and biomarkers associated with brain metastases in non-small cell lung cancer treated by tislelizumab plus chemotherapyShen Zhao, Wei Jiang, Nong Yang, et al.
Translational Lung Cancer Research|March 15, 2021
Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancerChuling Li, Meiqi Shi, Xinqing Lin, et al.
JTO Clinical and Research Reports|November 6, 2024
Analysis of Baseline Molecular Factors Associated With the Risk of Central Nervous System Progression Among Alectinib-Treated Patients With ALK-Positive NSCLCLianxi Song, Huan Yan, Qinqin Xu, et al.
Human Pathology|May 16, 2017
Elastic staining-a rejuvenated method to reassess prognosis and serosal invasion in patients with pT3N0M0 gastric cancerGuang Lei, Haiyan Yang, Ting Hong, et al.
Pageof 21

Showing results (61-70 of 208) with videos related to

Sort By:
Pageof 21
Clinical Therapeutics|October 27, 2010
The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover studyKun-Yan Li, Jian-Ping Liang, Bing-Qiang Hu, et al.
Natural Product Research|August 25, 2022
Flavonoids from the fruits of <i>Phyllanthus acidus</i> (L.) Skeels with anti-<i>α</i>-glucosidase activityJia Xu, Ying Xin, Hong-Tao Zhu, et al.
Tumori|January 29, 2021
Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspectiveYing-Hui Tong, Hai-Ying Ding, Wen-Xiu Xin, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 30, 2020
Pharmacokinetic and bioequivalence study of new S-1 capsule in Chinese cancer patientsYong Chen, Yun Jiang, Jingjing Qu, et al.
Oncotarget|February 1, 2018
The serum activity of thioredoxin reductases 1 (TrxR1) is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancerGong Chen, Qiong Chen, Fanxu Zeng, et al.
BMC Cancer|September 5, 2022
Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker studyYongchang Zhang, Lianxi Song, Liang Zeng, et al.
Translational Lung Cancer Research|March 18, 2024
Intracranial response pattern, tolerability and biomarkers associated with brain metastases in non-small cell lung cancer treated by tislelizumab plus chemotherapyShen Zhao, Wei Jiang, Nong Yang, et al.
Translational Lung Cancer Research|March 15, 2021
Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancerChuling Li, Meiqi Shi, Xinqing Lin, et al.
JTO Clinical and Research Reports|November 6, 2024
Analysis of Baseline Molecular Factors Associated With the Risk of Central Nervous System Progression Among Alectinib-Treated Patients With ALK-Positive NSCLCLianxi Song, Huan Yan, Qinqin Xu, et al.
Human Pathology|May 16, 2017
Elastic staining-a rejuvenated method to reassess prognosis and serosal invasion in patients with pT3N0M0 gastric cancerGuang Lei, Haiyan Yang, Ting Hong, et al.
Pageof 21